Sign In
Buy AXSM
$212.17
+1.13 (+0.535%)
At Close: Aug 04, 2026
AMRN, EPR among top gainers
01:21pm, Monday, 27'th Apr 2020
Axsome Therapeutics (NASDAQ:AXSM) +44% as Axsome's lead candidate successful in Alzheimer's study.Avadel Pharmaceuticals plc (NASDAQ:AVDL) +34% on positive data on lead drug.Yield10 Bioscience (NA
Avadel up 30% premarket on positive data on lead drug
12:01pm, Monday, 27'th Apr 2020
Avadel Pharmaceuticals (NASDAQ:AVDL) jumps 30% premarket on average volume in reaction to positive results from a Phase 3 clinical trial, REST-ON, evaluating lead candidate FT218, a once-nightly for
Statistically significant improvement in Alzheimer’s disease agitation, as measured by the CMAI total score compared to placebo (p=0.010, primary endpoint) Demonstrated rapid.
Statistically significant improvement in Alzheimer’s disease agitation, as measured by the CMAI total score compared to placebo (p=0.010, primary endpoint)...
Axsome Therapeutics price target raised to $131 from $125 at Cantor Fitzgerald AXSM
07:35am, Monday, 27'th Apr 2020
Axsome Therapeutics price target raised to $131 from $125 at Cantor Fitzgerald Cantor Fitzgerald AXSM
Axsome Therapeutics price target raised to $186 from $165 at Ladenburg AXSM
07:15am, Monday, 27'th Apr 2020
Axsome Therapeutics price target raised to $186 from $165 at Ladenburg Ladenburg AXSM
Why Axsome Is Touching The $100 Level For The First Time In Months
12:00am, Monday, 27'th Apr 2020
Axsome Therapeutics Inc (NASDAQ: AXSM), which was a high-flier for most of 2019, has come off the all-time highs reached late last year thanks to the COVID-19 pandemic and a...
Axsome Therapeutics (AXSM) - Investment Analysts' Recent Ratings Updates
05:22am, Friday, 17'th Apr 2020
Axsome Therapeutics (NASDAQ: AXSM) has recently received a number of price target changes and ratings updates: 4/14/2020 – Axsome Therapeutics is now covered by analysts at Cowen Inc. They set an �
2 Top Small-Cap Stocks to Buy Right Now
12:09pm, Wednesday, 15'th Apr 2020
These development-stage drug companies are well positioned for success, even amid the current market uncertainty.
Piper Sandler softens view on Cronos Group in premarket analyst action
11:08am, Tuesday, 14'th Apr 2020
Axsome Therapeutics (NASDAQ:AXSM) initiated with an Outperform rating and a $95 (58% upside) price target at Cowen and Company.Bellerophon Therapeutics (NASDAQ:BLPH) initiated with a Buy rating at Bro
Axsome Therapeutics initiated with an Outperform at Cowen AXSM
10:52am, Tuesday, 14'th Apr 2020
Axsome Therapeutics initiated with an Outperform at Cowen Cowen AXSM
The Week Ahead In Biotech: Urogen FDA Decision, Amarin, J&J Earnings And More COVID-19 Updates
05:44pm, Sunday, 12'th Apr 2020
Biotech stocks moved higher last week along with the broader market. The week witnessed a few clinical readouts and pre-announcements that reflected the coronavirus (COVID-19) impact.
Billionaires Are Gobbling Up These 3 Healthcare Stocks
08:13pm, Saturday, 11'th Apr 2020
These three developmental-stage pharma stocks are attracting some of the smartest investors right now.
Biotech Roundup: GSK’s Ante, Shakeup at Sage, Telehealth’s Rise & More
01:12pm, Friday, 10'th Apr 2020
The COVID-19 pandemic has stopped enrollment in many clinical trials and postponed the start of others but there is still life in the life sciences
Axsome's AXS-07 Meets Co-Primary Goals in Migraine Study
04:37pm, Tuesday, 07'th Apr 2020
Axsome's (AXSM) AXS-07 achieves both regulatory co-primary endpoints in the phase III INTERCEPT study for the early treatment of migraine.
